JMP Securities reissued their market outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Friday morning, Benzinga reports. JMP Securities currently has a $7.00 price objective on the stock.
Other analysts have also recently issued research reports about the company. Piper Sandler assumed coverage on Elevation Oncology in a research report on Friday, May 31st. They set an overweight rating and a $10.00 price target for the company. HC Wainwright reaffirmed a buy rating and set a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday, April 9th. Stephens assumed coverage on Elevation Oncology in a research report on Tuesday, May 14th. They set an overweight rating and a $8.00 price target for the company. Finally, Wedbush reaffirmed an outperform rating and set a $8.00 price target on shares of Elevation Oncology in a research report on Friday, May 3rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Elevation Oncology presently has an average rating of Buy and an average price target of $7.80.
Check Out Our Latest Stock Report on ELEV
Elevation Oncology Stock Up 5.9 %
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). As a group, analysts expect that Elevation Oncology will post -0.92 EPS for the current fiscal year.
Hedge Funds Weigh In On Elevation Oncology
Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Elevation Oncology during the 1st quarter valued at about $63,000. Affinity Asset Advisors LLC purchased a new position in shares of Elevation Oncology during the 1st quarter valued at about $6,509,000. Artal Group S.A. purchased a new position in shares of Elevation Oncology during the 1st quarter valued at about $7,762,000. Vanguard Group Inc. raised its stake in shares of Elevation Oncology by 30.8% during the 1st quarter. Vanguard Group Inc. now owns 1,532,045 shares of the company’s stock valued at $7,859,000 after buying an additional 360,799 shares during the last quarter. Finally, Darwin Global Management Ltd. purchased a new position in shares of Elevation Oncology in the 1st quarter valued at about $11,968,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.
Elevation Oncology Company Profile
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Read More
- Five stocks we like better than Elevation Oncology
- ESG Stocks, What Investors Should Know
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Investors Need to Know to Beat the Market
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.